Abstract
There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Clinical Pharmacology and Therapeutics |
| Jahrgang | 102 |
| Ausgabenummer | 2 |
| Seiten (von - bis) | 197-199 |
| Seitenumfang | 3 |
| ISSN | 0009-9236 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 01.08.2017 |
Fördermittel
B.F. is supported by an Adumed Research stipend. W.H.Z. is supported by the DZHK (German Center for Cardiovascular Research), the German Federal Ministry for Science and Education (BMBF FKZ 13GW0007A (CIRM-ET3)), the German Research Foundation (DFG ZI 708/10-1; SFB 937 TP18, SFB 1002 TPs C04, S1; IRTG 1618 RP12), the European Union FP7 CARE-MI, the Foundation Leducq, and the National Institutes of Health (U01HL099997).
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
Fingerprint
Untersuchen Sie die Forschungsthemen von „Engineered Heart Repair“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver